Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2a Trial to Evaluate the Safety, Tolerability and Efficacy of Nebulised RESP30X Nitric Oxide Formulations in Non-Cystic Fibrosis Bronchiectasis (NCFB) Patients With Pseudomonas Aeruginosa (Pa) or Other Potentially Pathogenic Micro-organisms (PPMs)

NCT06663176 is registered in ClinicalTrials.gov with Thirty Respiratory Limited as lead sponsor.

NCT NCT06663176
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06663176 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2a Trial to Evaluate the Safety, Tolerability and Efficacy of Nebulised RESP30X Nitric Oxide Formulations in Non-Cystic Fibrosis Bronchiectasis (NCFB) Patients With Pseudomonas Aeruginosa (Pa) or Other Potentially Pathogenic Micro-organisms (PPMs)
Lead sponsor
Thirty Respiratory Limited
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 16, 2024
Completion date
May 5, 2028
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-cystic fibrosis bronchiectasis